Lung Cancer | Specialty

Immunotherapy Combos Continue to Excel in NSCLC, But Patient Selection Must Be Optimized

October 23rd 2020

In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.

Afatinib Efficacious in EGFR+ NSCLC Harboring Major Uncommon Mutations, Irrespective of Ethnicity

October 23rd 2020

Afatinib was found to be effective when used in Asian and non-Asian patients with non–small cell lung cancer with major uncommon and compound EGFR mutations, irrespective of ethnicity.

Evaluating New Standards in Extensive-Stage Small Cell Lung Cancer

October 23rd 2020

Igor I. Rybkin, MD, PhD, discusses the data with these frontline and second-line regimens in extensive-stage small cell lung cancer.

Subbiah Addresses Controversy Surrounding Pembrolizumab Approval for TMB-High Tumors

October 22nd 2020

In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.

Real World Data Show Afatinib as Effective, Safe in Second-Line Metastatic Squamous Lung Cancer

October 21st 2020

Afatinib was found to be effective and well tolerated when used as a second-line treatment in patients with metastatic squamous carcinoma of the lung.

FDA Grants Priority Review to Adjuvant Osimertinib for Early-Stage EGFR+ Lung Cancer

October 20th 2020

The FDA has granted osimertinib a priority review designation to a supplemental new drug application for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

PLCOm2012 Risk Prediction Model Is Highly Sensitive in Identifying African American Ever-Smokers With Lung Cancer

October 20th 2020

The PLCOm2012 risk prediction model is a preferable lung cancer screening method for identifying African American ever-smokers over the current United States Preventive Services Task Force lung cancer screening eligibility criteria, which may help to overcome racial disparities.

Paradigm Shift for Early EGFR+ NSCLC

October 20th 2020

Practical Implications of ADAURA in NSCLC

October 20th 2020

Unprecedented Results from ADAURA

October 20th 2020

Adjuvant Approaches in EGFR+ NSCLC

October 20th 2020

Standard of Care for EGFR+ ES-NSCLC

October 20th 2020

Testing for EGFR in NSCLC Worldwide

October 20th 2020

Molecular Testing in Early-Stage NSCLC

October 20th 2020

Determining Resectability in ES-NSCLC

October 20th 2020

Clinical Evaluation of ES-NSCLC in Japan

October 20th 2020

Pembrolizumab Combos Showcase Promising Safety, Antitumor Activity in NSCLC

October 19th 2020

Pembrolizumab has demonstrated promising activity when used in combination with chemotherapy or quavonlimab in select patients with nonsquamous or advanced non–small cell lung cancer.

Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC

October 19th 2020

Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.

Investigators Tackle New NSCLC Target With Glutaminase Inhibitor

October 19th 2020

Telaglenastat, a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.